🔎 Trials Near Me

Home › Burkitt Lymphoma › Iowa › Cedar Rapids

Burkitt Lymphoma clinical trials in Cedar Rapids, IA

6 studies for Burkitt Lymphoma are looking for participants at sites in and around Cedar Rapids (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

RecruitingPhase 3
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi away
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RecruitingPhase 1/2
  • University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City · 25 mi away
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingPhase 2
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi away
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RecruitingPhase 3
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi away
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

RecruitingPhase 1/2
  • Research Site, Iowa City · 25 mi away
Ages 12 and older · All sexes · Updated Jul 13, 2026 · NCT07109219

Burkitt Lymphoma trials in other cities

Other studies in Cedar Rapids

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.